C-Src/Cav1-dependent activation of the EGFR by Dsg2

Oncotarget

Volumn 7, Issue 25, 2016, Pages 37536-37555

  Overmiller, Andrew M ^a   McGuinn, Kathleen P ^a   Roberts, Brett J ^b   Cooper, Felicia ^a   Brennan Crispi, Donna M ^a   Deguchi, Takahiro ^c   Peltonen, Sirkku ^c   Wahl, James K ^b   Mahoney, My G ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

C Src; Caveolin 1; Desmoglein 2; EGFR; Stat3

Indexed keywords

CAVEOLIN 1; DESMOGLEIN 2; EPIDERMAL GROWTH FACTOR RECEPTOR; METHYL BETA CYCLODEXTRIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; STAT3 PROTEIN; SUCROSE; CAV1 PROTEIN, HUMAN; CSK TYROSINE-PROTEIN KINASE; DSG2 PROTEIN, HUMAN; EGFR PROTEIN, HUMAN;

A431 CELL LINE; ARTICLE; CANCER CELL LINE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DESMOSOME; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FRACTIONATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; KERATINOCYTE; LIPID RAFT; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SKIN CARCINOMA; BIOSYNTHESIS; CELL MOTION; ENZYMOLOGY; FIBROSARCOMA; GENETICS; MEMBRANE MICRODOMAIN; METABOLISM; PHYSIOLOGY; SKIN TUMOR; TUMOR CELL LINE; UPREGULATION;

CAVEOLIN 1; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DESMOGLEIN 2; FIBROSARCOMA; HUMANS; MEMBRANE MICRODOMAINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; SRC-FAMILY KINASES; UP-REGULATION;

EID: 84978086444     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7675     Document Type: Article

References (75)

1. Mahoney MG, Hu Y, Brennan D, Bazzi H, Christiano AM and Wahl JKR. Delineation of diversified desmoglein distribution in stratified squamous epithelia: implications in diseases. Exp Dermatol. 2006; 15:101-109.
2. Holthöfer B, Windoffer R, Troyanovsky S and Leube RE. Structure and function of desmosomes. Int Rev Cytol. 2007; 264:65-163.
3. Pilichou K, Nava A, Basso C, Beffagna G, Bauce B, Lorenzon A, Frigo G, Vettori A, Valente M, Towbin J, Thiene G, Danieli GA and Rampazzo A. Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy. Circulation. 2006; 113:1171-1179.
4. Wang H, Li ZY, Liu Y, Persson J, Beyer I, Möller T, Koyuncu D, Drescher MR, Strauss R, Zhang XB, Wahl JKR, Urban N, Drescher C, Hemminki A, Fender P and Lieber A. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med. 2011; 17:96-104.
5. Camargo LM, Zhang XD, Loerch P, Caceres RM, Marine SD, Uva P, Ferrer M, de Rinaldis E, Stone DJ, Majercak J, Ray WJ, Yi-An C, Shearman MS and Mizuguchi K. Pathway-based analysis of genome-wide siRNA screens reveals the regulatory landscape of APP processing. PLoS One. 2015; 10:e0115369.
6. Kamekura R, Nava P, Feng M, Quiros M, Nishio H, Weber DA, Parkos CA and Nusrat A. Inflammation-induced desmoglein-2 ectodomain shedding compromises the mucosal barrier. Mol Biol Cell. 2015; 26:3165-3177.
7. Eshkind L, Tian Q, Schmidt A, Franke WW, Windoffer R and Leube RE. Loss of desmoglein 2 suggests essential functions for early embryonic development and proliferation of embryonal stem cells. Eur J Cell Biol. 2002; 81:592-598.
8. Brennan D, Hu Y, Joubeh S, Choi YW, Whitaker-Menezes D, O'Brien T, Uitto J, Rodeck U and Mahoney MG. Suprabasal Dsg2 expression in transgenic mouse skin confers a hyperproliferative and apoptosis-resistant phenotype to keratinocytes. J Cell Science. 2007; 120:758-771.
9. Brennan D and Mahoney MG. Increased expression of Dsg2 in malignant skin carcinomas: A tissue-microarray based study. Cell Adh Migr. 2009; 3:148-154.
10. Kurzen H, Munzing I and Hartschuh W. Expression of desmosomal proteins in squamous cell carcinomas of the skin. J Cutan Pathol. 2003; 30:621-630.
11. Schäfer S, Koch PJ and Franke WW. Identification of the ubiquitous human desmoglein, Dsg2, and the expression catalogue of the desmoglein subfamily of desmosomal cadherins. Exp Cell Res. 1994; 211:391-399.
12. Denning MF, Guy SG, Ellerbroek SM, Norvell SM, Kowalczyk AP and Green KJ. The expression of desmoglein isoforms in cultured human keratinocytes is regulated by calcium, serum, and protein kinase C. Exp Cell Res. 1998; 239:50-59.
13. Barber AG, Castillo-Martin M, Bonal DM, Rybicki BA, Christiano AM and Cordon-Cardo C. Characterization of desmoglein expression in the normal prostatic gland. Desmoglein 2 is an independent prognostic factor for aggressive prostate cancer. PLoS One. 2014; 9:e98786.
14. Abulrob A, Giuseppin S, Andrade MF, McDermid A, Moreno M and Stanimirovic D. Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae. Oncogene. 2004; 23:6967-6979.
15. Teh MT, Parkinson EK, Thurlow JK, Liu F, Fortune F and Wan H. A molecular study of desmosomes identifies a desmoglein isoform switch in head and neck squamous cell carcinoma. J Oral Pathol Med. 2011; 40:67-76.
16. Biedermann K, Vogelsang H, Becker I, Plaschke S, Siewert JR, Hofler H and Keller G. Desmoglein 2 is expressed abnormally rather than mutated in familial and sporadic gastric cancer. J Pathol. 2005; 207:199-206.
17. Kamekura R, Kolegraff KN, Nava P, Hilgarth RS, Feng M, Parkos CA and Nusrat A. Loss of the desmosomal cadherin desmoglein-2 suppresses colon cancer cell proliferation through EGFR signaling. Oncogene. 2013; 33:4531-4536.
18. Yashiro M, Nishioka N and Hirakawa K. Decreased expression of the adhesion molecule desmoglein-2 is associated with diffuse-type gastric carcinoma. Eur J Cancer. 2006; 14:2397-2403.
19. Gupta A, Nitoiu D, Brennan-Crispi D, Addya S, Riobo NA, Kelsell DP and Mahoney MG. Cell cycle-and cancerassociated gene networks activated by Dsg2: evidence of cystatin A deregulation and a potential role in cell-cell adhesion. PloS One. 2015; 10:e0120091.
20. Tong J, Taylor P and Moran MF. Proteomic analysis of the epidermal growth factor receptor (EGFR) interactome and post-translational modifications associated with receptor endocytosis in response to EGF and stress. Mol Cell Proteomics. 2014; 13:1644-1658.
21. Brennan-Crispi DM, Hossain C, Sahu J, Brady M, Riobo NA and Mahoney MG. Crosstalk between Desmoglein 2 and Patched1 accelerates chemical-induced skin tumorigenesis. Oncotarget. 2015; 6:8593-8605. doi: 10.18632/oncotarget.3309.
22. Brennan D, Peltonen S, Dowling A, Medhat W, Green KJ, Wahl JK, Del Galdo F and Mahoney MG. A role for caveolin-1 in desmoglein binding and desmosome dynamics. Oncogene. 2012; 31:1636-1648.
23. Simons K and Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000; 1:31-39.
24. Staubach S and Hanisch FG. Lipid rafts: signaling and sorting platforms of cells and their roles in cancer. Expert Rev Proteomics. 2011; 8:263-277.
25. Fridolfsson HN, Roth DM, Insel PA and Patel HH. Regulation of intracellular signaling and function by caveolin. FASEB J. 2014; 28:3823-3831.
26. Couet J, Li S, Okamoto T, Ikezu T and Lisanti MP. Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J Biol Chem. 1997; 272:6525-6533.
27. Lee SW, Reimer CL, Oh P, Campbell DB and Schnitzer JE. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene. 1998; 16:1391-1397.
28. Engelman JA, C.C. W, Yasuhara S, Song KS, Okamoto T and Lisanti MP. Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorageindependent growth. 1997; 272:16374-16381.
29. Kim YN, Dam P and Bertics PJ. Caveolin-1 phosphorylation in human squamous and epidermoid carcinoma cells: dependence on ErbB1 expression and Src activation. Exp Cell Res. 2002; 280:134-147.
30. Orlichenko L, Huang B, Krueger E and McNiven MA. Epithelial growth factor-induced phosphorylation of caveolin 1 at tyrosine 14 stimulates caveolae formation in epithelial cells. J Biol Chem 2006; 281:4570-4579.
31. Mineo C, Gill GN and Anderson RG. Regulated migration of epidermal growth factor receptor from caveolae. J Biol Chem. 1999; 274:30636-30643.
32. Agelaki S, Spiliotaki M, Markomanolaki H, Kallergi G, Mavroudis D, Georgoulias V and Stournaras C. Caveolin-1 regulates EGFR signaling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition. Cancer Biol Ther 2009; 8:1470-1477.
33. Klessner JL, Desai BV, Amargo EV, Getsios S and Green KJ. EGFR and ADAMs cooperate to regulate shedding and endocytic trafficking of the desmosomal cadherin desmoglein 2. Mol Biol Cell. 2009; 20:328-337.
34. Lorch JH, Klessner J, Park JK, Getsios S, Wu YL, Stack MS and Green KJ. Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells. J Biol Chem. 2004; 279:37191-37200.
35. Gaudry CA, Palka HL, Dusek RL, Huen AC, Khandekar MJ, Hudson LG and Green KJ. Tyrosine-phosphorylated plakoglobin is associated with desmogleins but not desmoplakin after epidermal growth factor receptor activation. J Biol Chem. 2001; 276:24871-24880.
36. Hackel PO, Zwick E, Prenzel N and Ullrich A. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 1999; 11:184-189.
37. Chung J, Uchida E, Grammer TC and Blenis J. STAT3 serine phosphorylation by ERK-dependent and-independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol. 1997; 17:6508-6516.
38. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH and Parsons SJ. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 andTyr1101 is associated with modulation of receptor function. J Biol Chem. 1999; 274:8335-8343.
39. Olayioye MA, Beuvink, I., Horsch K, Daly JM and Hynes NE. ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem. 1999; 274:17209-17218.
40. Keilhack H, Tenev T, Nyakatura E, Godovac-Zimmermann J, Nielsen L, Seedorf K and Böhmer FD. Phosphotyrosine 1173 mediates binding of the protein-tyrosine phosphatase SHP-1 to the epidermal growth factor receptor and attenuation of receptor signaling. J Biol Chem. 1998; 273:24839-24846.
41. Suomela S, Elomaa O, Skoog T, Ala-Aho R, Jeskanen L, Pärssinen J, Latonen L, Grénman R, Kere J, Kähäri VM and Saarialho-Kere U. CCHCR1 is up-regulated in skin cancer and associated with EGFR expression. PLoS One. 2009; 4:e6030.
42. Graness A, Hanke S, Boehmer FD, Presek P and Liebmann C. Protein-tyrosine-phosphatase-mediated epidermal growth factor (EGF) receptor transinactivation and EGF receptor-independent stimulation of mitogen-activated protein kinase by bradykinin in A431 cells. Biochem J. 2000; 347:441-447.
43. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH and Parsons SJ. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem. 1999; 274:8335-8343.
44. Quadros MR, Peruzzi F, Kari C and Rodeck U. Complex regulation of signal transducers and activators of transcription 3 activation in normal and malignant keratinocytes. Cancer Res. 2004; 64:3934-3939.
45. Xiong A, Yang Z, Shen Y, Zhou J and Shen Q. Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention. Cancers (Basel). 2014; 6:926-957.
46. Barnes CJ, Bagheri-Yarmand R, Mandal M, Yang Z, Clayman GL, Hong WK and Kumar R. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol Cancer Ther. 2003; 2:345-351.
47. Kansra S, Stoll SW, Johnson JL and Elder JT. Src family kinase inhibitors block amphiregulin-mediated autocrine ErbB signaling in normal human keratinocytes. Mol Pharmacol. 2005; 67:1145-1157.
48. Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M, Cascone T, Mills GB, Heymach JV and Johnso nFM. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res 2009; 15:6852-6861.
49. Lajoie P and Nabi IR. Regulation of raft-dependent endocytosis. J Cell Mol Med. 2007; 11:644-653.
50. Li S, Couet J and Lisanti MP. Src tyrosine kinases, Galpha subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem 1996; 271:29182-29190.
51. Hell SW and Wichmann J. Breaking the diffraction resolution limit by stimulated emission: stimulatedemission-depletion fluorescence microscopy. Opt Lett. 1994; 19:780-782.
52. Craven RJ, Lightfoot H and Cance WG. A decade of tyrosine kinases: from gene discovery to therapeutics. Surg Oncol. 2003; 12:39-49.
53. Jost M, Huggett TM, Kari C and Rodeck U. Matrixindependent survival of human keratinocytes through an EGF receptor/MAPK-kinase-dependent pathway. Mol Biol Cell. 2001; 12:1519-1527.
54. Andl CD, Mizushima T, Nakagawa H, Oyama K, Harada H, Chruma K, Herlyn M and Rustgi AK. Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo. J Biol Chem. 2003; 278:1824-1830.
55. Chitaev NA and Troyanovsky SM. Direct Ca2+ dependent heterophilic interaction between desmosomal cadherins, desmoglein and desmocollin, contributes to cell adhesion. J Cell Biol. 1997; 138:193-201.
56. Jiang K, Rankin CR, Nava P, Sumagin R, Kamekura R, Stowell SR, Feng M, Parkos CA and Nusrat A. Galectin-3 regulates desmoglein-2 and intestinal epithelial intercellular adhesion. J Biol Chem. 2014; 289:10510-10517.
57. Irwin ME, Bohin N and Boerner JL. Src family kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer cells. Cancer Biol Ther. 2011; 12:718-726.
58. Goh LK, Huang F, Kim W, Gygi S and Sorkin A. Multiple mechanisms collectively regulate clathrin-mediated endocytosis of the epidermal growth factor receptor. J Cell Biol. 2010; 189:871-883.
59. Roepstorff K, Grøvdal L, Grandal M, Lerdrup M and van Deurs B. Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. Histochem Cell Biol. 2008; 129:563-578.
60. Madshus IH and Stang E. Internalization and intracellular sorting of the EGF receptor: a model for understanding the mechanisms of receptor trafficking. J Cell Sci. 2009; 122:3433-3439.
61. Lambert S, Vind-Kezunovic D, Karvinen S and Gniadecki R. Ligand-independent activation of the EGFR by lipid raft disruption. J Invest Dermatol. 2006; 126:954-962.
62. Jans R, Atanasova G, Jadot M and Poumay Y. Cholesterol depletion upregulates involucrin expression in epidermal keratinocytes through activation of p38. J Invest Dermatol. 2004; 123:564-573.
63. Mathay C, Pierre M, Pittelkow MR, Depiereux E, Nikkels AF, Colige A and Poumay Y. Transcriptional profiling after lipid raft disruption in keratinocytes identifies critical mediators of atopic dermatitis pathways. J Invest Dermatol. 2011; 131:46-58.
64. Goetz JG, Lajoie P, Wiseman SM and Nabi IR. Caveolin-1 in tumor progression: the good, the bad and the ugly. Cancer Metastasis Rev. 2008; 27:715-735.
65. Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN and Ueno NT. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012; 136:331-345.
66. Antonarakis ES, Carducci MA and Eisenberger MA. Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett. 2010; 291:1-13.
67. Haghgoo SM, Allameh A, Mortaz E, Garssen J, Folkerts G, Barnes PJ and Adcock IM. Pharmacogenomics and targeted therapy of Cancer: Focusing on Non-small cell lung Cancer. Eur J Pharmacol. 2015; S0014-2999:00136-00133.
68. Zhang S and Yu D. Targeting Src family kinases in anticancer therapies: turning promise into triumph. Trends Pharmacol Sci 2012; 33:122-128.
69. Liu J, Wang H, Qu A, Li J, Zhao Y and Wang J. Combined effects of C225 and 125-iodine seed radiation on colorectal cancer cells. Radiat Oncol. 2013; 8:219.
70. Reigneau M, Robert C, Routier E, Mamelle G, Moya-Plana A, Tomasic G and Mateus C. Efficacy of neoadjuvant cetuximab alone or with platinum salt and fluorouracil for the treatment of unresectable locally advanced cutaneous squamous cell carcinomas. Br J Dermatol. 2015; 173:527-534.
71. Lewis CM, Glisson BS, Feng L, Wan F, Tang X, Wistuba II, El-Naggar AK, Rosenthal DI, Chambers MS, Lustig RA and Weber RS. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012; 18:1435-1446.
72. Wahl JK, Sacco PA, MaGranahan-Sadler TM, Sauppe LM, Wheelock MJ and Johnson KR. Plakoglobin domains that define its association with the desmosomal cadherins and the classical cadherins: identification of unique and shared domains. J Cell Sci. 1996; 109:1143-1154.
73. Keim SA, Johnson KR, Wheelock MJ and Wahl JKR. Generation and characterization of monoclonal antibodies against the proregion of human desmoglein-2. Hybridoma (Larchmt). 2008; 27:249-258.
74. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A and Fusenig NE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol. 1988; 106:761-771.
75. Schoop VM, Mirancea N and Fusenig NE. Epidermal organization and differentiation of HaCaT keratinocytes in organotypic coculture with human dermal fibroblasts. J Invest Dermatol 1999; 112:343-353.